cholecalciferol and Hyperuricemia

Hyperuricemia is common among patients with chronic kidney disease (CKD). In the general population, hyperuricemia is associated with secondary hyperparathyroidism (SHPT), in a mechanism that involves vitamin D metabolism. Data for patients with CKD, however, are scarce. We aimed to evaluate the relationship between hyperuricemia and mineral and bone metabolism, particularly hyperparathyroidism.. This is a retrospective study that included 922 adult patients with stages 3, 4, or 5 CKD, not on dialysis. Clinical, demographic, and biochemical data were collected from charts and included uric acid, parathyroid hormone (PTH), 25(OH)-vitamin D, calcium, phosphate, renal function (estimated glomerular filtration rate-eGFR), and medications such as allopurinol, furosemide, and cholecalciferol. SHPT was defined as PTH > 65 pg/ml.. Our patients were mostly Caucasian women, with a mean age of 64 ± 16 years. SHPT and hyperuricemia were observed in 70% and 62.4% of patients, respectively. Patients with SHPT presented higher levels of uric acid (7.2 ± 1.8 vs. 6.6 ± 1.7 mg/dL, p = 0.0001) and a higher frequency of hyperuricemia (66% vs. 33%, p = 0.0001). Patients with hyperuricemia were mostly female, with lower eGFR, higher phosphate, and higher PTH. The risk of hypovitaminosis D was higher among patients with SHPT (69.7% vs. 53.1%, p = 0.0001). Hyperuricemia remained independently associated with hyperparathyroidism, (p = 0.033) even after adjustments for eGFR, calcium, phosphate, hypovitaminosis D, and use of allopurinol, calcitriol, furosemide, and cholecalciferol.. Hyperuricemia seems to be a contributing factor for SHPT in patients with CKD. The mechanisms behind this finding have yet to be elucidated.

Topics: Adult; Aged; Aged, 80 and over; Allopurinol; Calcium; Cholecalciferol; Female; Furosemide; Humans; Hyperparathyroidism, Secondary; Hyperuricemia; Male; Middle Aged; Parathyroid Hormone; Phosphates; Renal Insufficiency, Chronic; Retrospective Studies; Uric Acid; Vitamin D; Vitamin D Deficiency

Previous studies have shown that hyperuricemia is involved in diabetes, obesity, hypertension, chronic kidney disease, and other diseases. At the same time, studies have shown that vitamin D3 levels in the body are linked to the onset of diabetes. However, there is currently no sufficient evidence to prove whether this connection is affected by the uric acid level. Therefore, we attempted to investigate the association between vitamin D3 content and the occurrence of diabetes in populations with different uric acid levels though the data of NHANES database from 2009 to 2018.. Using the NHANES database, we performed a cross-sectional analysis. The participants were chosen based on stringent inclusion and exclusion requirements. This study finally included a total number of 16,735 individuals. Multivariate logistic regression analysis was used to investigate the association between vitamin D3 and diabetes mellitus in hyperuricemia and non-hyperuricemia patients after complete adjustment, and multivariate linear regression analysis was used to illustrate the association between vitamin D3 and uric acid.. The results showed that the association between vitamin D3 and diabetes was weakened in hyperuricemia patients (OR 0.95 (0.92,0.98)). An independent association was discovered between vitamin D3 and uric acid (β -0.12 (-0.16, -0.07)) in all groups of population.. This study shows that vitamin D3 content is associated with the incidence of diabetes in people with high level of uric acid. This study offers a fresh perspective on the elements that influence the etiology of diabetes in hyperuricemia patients.

Topics: Cholecalciferol; Cross-Sectional Studies; Diabetes Mellitus; Humans; Hyperuricemia; Nutrition Surveys; Risk Factors

Topics: AMP-Activated Protein Kinases; Animals; Blood Glucose; Cholecalciferol; Creatinine; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1; Hyperuricemia; Hypoglycemic Agents; Insulin Resistance; Kidney; Kidney Cortex; Male; Malondialdehyde; MAP Kinase Signaling System; NADP; Oxidative Stress; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Sirtuin 1; Sodium Chloride; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Urea; Uric Acid; Vildagliptin